Oncology Billing Services Across Chemotherapy, Radiation, and Hematology Procedures
Oncology billing is the highest financial-risk billing environment in all of physician practice. A single missed prior authorization on a high-cost chemotherapy agent represents tens of thousands of dollars in drug cost the practice cannot recover. Medical oncology billing, radiation oncology billing, and hematology-oncology billing each operate under entirely different code sets, drug billing rules, and prior authorization requirements. MBC oncology billing services manage every category with the specialty-specific precision that cancer care revenue demands.
Performance data from MBC-managed oncology practices across medical oncology, radiation oncology, and hematology-oncology programs
Oncology Billing Losses That Compound Faster Than Any Other Specialty
Oncology billing losses are categorically different from other specialties. A denied J-code for a chemotherapy drug does not just lose the billing fee. It loses the full drug acquisition cost the practice already paid. A single uncollected high-cost biologic claim can exceed the total annual billing error exposure of an entire primary care practice. Every billing gap in oncology compounds at the cost of the drug, not just the service.
Current Regulatory Updates Affecting Oncology Billing
Three Policy Changes Directly Impacting Oncology Billing Services Revenue
IRA Drug Negotiation and Medicare Part B Oncology Drug Reimbursement Changes
The Inflation Reduction Act allows CMS to negotiate prices for high-cost Medicare Part B drugs including oncology agents. As negotiated prices take effect, the ASP-based reimbursement formula that determines J-code payment rates for oncology drugs changes. Medical oncology and hematology-oncology practices must monitor J-code reimbursement rates against drug acquisition costs on every affected agent to ensure the practice is not administering drugs at a financial loss due to reimbursement rate changes they have not tracked.
CMS Prior Authorization Expansion for Oncology Drugs Under Medicare Advantage
Medicare Advantage plans have significantly expanded prior authorization requirements for oncology drugs, targeted therapies, and immunotherapy agents. CMS finalized new rules requiring Medicare Advantage plans to respond to prior authorization requests within specified timeframes for oncology patients, but the volume and complexity of required documentation continues to increase. Oncology practices without dedicated prior authorization staff and systematic tracking workflows face a growing administrative burden that directly affects treatment timelines and revenue recovery.
Radiation Oncology Alternative Payment Model and RBRVS Rate Updates
CMS has pursued a Radiation Oncology Alternative Payment Model that would bundle radiation oncology billing payments by episode rather than by individual treatment session. While full implementation has been delayed, the underlying reimbursement restructuring of radiation oncology billing codes continues. Radiation oncology practices must monitor both the current fee-for-service RBRVS rates and the trajectory of bundled payment models to maintain accurate financial projections and billing workflow planning.
Oncology-Specific Billing Challenges
Why Generic Billing Companies Cannot Manage Oncology Revenue at the Required Precision
Oncology billing errors are not just revenue losses. They are drug cost write-offs, prior authorization compliance failures, and audit exposures that no generalist billing company is built to prevent.
Prior Authorization Failures on High-Cost Chemotherapy Agents
Every chemotherapy drug, targeted therapy, and immunotherapy agent requires prior authorization from commercial payers and Medicare Advantage plans. When authorization is not obtained before the first administration, expires mid-treatment cycle, or is obtained for the wrong drug or dosage, the J-code claim is denied and the practice absorbs the full drug acquisition cost. For a practice administering a single checkpoint inhibitor at $15,000 per infusion, one missed authorization represents a five-figure drug cost write-off on a single encounter.
Chemotherapy J-Code and NDC Documentation Errors
Every chemotherapy drug billed requires the correct J-code matched to the drug name and formulation, the correct units matching the documented dose administered, and the NDC number of the specific drug lot used. When any of these three elements is missing or incorrect, the drug claim is denied or underpaid. At 5.2x higher denial rate for practices without systematic NDC documentation, J-code billing errors represent the highest-volume denial category in medical oncology billing, and each denied claim represents the full drug acquisition cost at risk.
Chemotherapy Infusion Add-On Hour Undercoding
Chemotherapy infusion billing requires the initial infusion code for the first hour and add-on codes for each additional hour of infusion time. When the infusion record does not explicitly document start and stop times per drug administered, the billing team cannot substantiate additional hours and defaults to billing only the initial infusion code. At 44% undercoding rate across oncology infusion claims, this single documentation gap costs medical oncology practices tens of thousands of dollars monthly across their infusion chair volume.
Radiation Oncology Session Billing Gaps Across Multi-Week Treatment Courses
Radiation oncology billing requires a separate claim for every treatment session delivered across a multi-week course of radiation. When treatment sessions are missed in the billing workflow, the practice delivers the service but never captures the payment. For a 30-fraction IMRT course, a 10% session billing gap represents 3 unbilled treatment delivery codes per patient. Across a high-volume radiation oncology program treating hundreds of patients, systematic session billing gaps compound into six-figure annual revenue losses before anyone identifies the pattern.
Hematology-Oncology Procedure Billing Errors on Bone Marrow and Flow Cytometry
Hematology-oncology billing for bone marrow aspiration, bone marrow biopsy, and flow cytometry requires correct code selection based on the number of procedures performed and the number of markers analyzed. When both aspiration and biopsy are performed, 38222 covers both rather than separate billing of 38220 and 38221. Flow cytometry units depend on marker count. Documentation gaps that prevent the billing team from confirming the number of markers analyzed force billing at the lowest applicable flow cytometry code, losing revenue on every complex hematologic workup.
Oncology E/M Undercoding on Highly Complex Cancer Management Visits
Medical oncology and hematology-oncology E/M visits managing active cancer treatment represent some of the highest-complexity outpatient encounters in all of medicine. Patients on active chemotherapy with multiple treatment-related toxicities, extensive lab and imaging data under review, and high-risk treatment decisions consistently qualify for 99215 on established visits. Systematic undercoding at 99213 or 99214 on cancer management visits that qualify for 99215 represents per-visit revenue loss across a patient panel where every visit is genuinely complex.
Enterprise Oncology RCM
Oncology Billing Services Engineered for Drug Cost Protection and Full Treatment Capture
Oncology billing is not a billing efficiency problem. It is a drug cost protection problem. Every workflow at MBC is built to protect the practice from the financial exposure that occurs when prior authorization, J-code billing, and infusion documentation fail simultaneously. Learn more about our revenue cycle management services.
Oncology Prior Authorization Management Across Every Drug and Cycle
Dedicated prior authorization workflow for every chemotherapy agent, targeted therapy, and immunotherapy drug. Authorization obtained before the first administration of every treatment cycle. Expiration tracked per patient with renewal alerts before the next cycle begins. Authorization confirmed against the specific drug, dosage, and diagnosis code before the infusion chair is scheduled. No chemotherapy claim is submitted without confirmed active authorization.
Chemotherapy J-Code and NDC Billing Accuracy
Every chemotherapy drug claim reviewed for correct J-code, correct units matching the documented administered dose, and NDC number from the specific drug lot used at the time of infusion. J-code billing is reconciled against the pharmacy dispensing record and the infusion administration record before claim submission. Drug claim denial rate is monitored at the J-code level and reported monthly so systematic errors in any drug category are caught before they become quarterly revenue problems.
Infusion Administration Billing with Full Add-On Hour Capture
Every infusion record reviewed for start time, stop time, and drug-specific administration duration before infusion codes are assigned. Initial infusion codes billed with correct add-on hours documented per drug. Sequential and concurrent infusion add-on codes applied when multiple agents are administered in the same session. Infusion time documentation gaps are identified and queried before the claim is submitted, not discovered after payment posting reveals undercoding.
Radiation Oncology Session Billing Across Full Treatment Courses
Every radiation treatment session tracked from planning through the final delivery fraction. Treatment planning, simulation, and each delivery session billed in the correct sequence. IMRT, SBRT, and image-guided radiation therapy codes applied with the correct delivery modality codes. Session billing is reconciled against the treatment record at the end of each week of treatment to catch missing sessions before the billing window closes. No radiation treatment session delivered goes unbilled.
Hematology-Oncology Procedure and Flow Cytometry Billing Accuracy
Bone marrow aspiration, biopsy, and combined procedure coding applied correctly based on documentation of procedures performed. Flow cytometry units billed based on the number of markers analyzed and documented. Blood transfusion administration codes applied per unit transfused with add-on codes for each additional unit. Every hematology-oncology procedure reviewed against the pathology and lab reports before code selection is finalized.
Oncology E/M Level Optimization for Active Cancer Treatment Visits
Every oncology office visit reviewed against documented MDM complexity before E/M level is finalized. Active cancer management visits with treatment-related toxicity assessment, extensive lab and imaging data review, and high-risk chemotherapy management decisions are coded at 99215 where documentation supports it. Provider-level E/M distribution monitored quarterly so systematic undercoding on complex cancer management visits is identified before it compounds into annual revenue loss.
Oncology Billing Code Reference
Mastering Every CPT Code for Oncology Billing Services
Oncology CPT codes span chemotherapy administration, radiation planning and delivery, hematology procedures, drug J-codes, and supportive care. Our specialists apply every code correctly across every treatment category.
Medical Oncology Billing: Chemotherapy Administration (96401-96417)
| CPT Code | Description | Oncology Billing Note |
|---|---|---|
| 96401 / 96402 | Chemotherapy SQ or IM Injection: Non-Hormonal (96401) and Hormonal (96402) | Bill per injection. Document drug, dose, route, and site. Bill the drug J-code separately. Add E/M with modifier 25 when a separately identifiable visit also occurs. |
| 96413 / 96415 | Chemo IV Infusion: First Hour (96413) and Each Additional Hour (96415) | Document start and stop times per drug. Missing time documentation forces billing at 96413 only, losing all add-on hour revenue. Every 96415 unit requires documented time support. |
| 96409 / 96411 | Chemotherapy IV Push: Initial (96409) and Each Additional Sequential Push (96411) | Use for infusions completed in 15 minutes or less. Do not use 96415 hourly add-on for IV push drugs. Document push administration separately from infusion drugs. |
Radiation Oncology Billing: Planning (77261-77263), IMRT (77385-77386), and SBRT (77373)
| CPT Code | Description | Oncology Billing Note |
|---|---|---|
| 77261-77263 | Radiation Treatment Planning: Simple (77261), Intermediate (77262), Complex (77263) | Bill once per treatment course, not per session. IMRT planning uses 77301 separately. Document dose constraints and physician approval before billing. |
| 77385 / 77386 | IMRT Delivery: Simple (77385) and Complex (77386) Per Treatment Session | Bill per session delivered. Track every fraction from simulation through the final session. Bill image guidance (77387) separately when used each session. |
| 77373 | SBRT Delivery Per Session (Typically 3-5 Fractions Per Course) | Requires separate planning (77299) and image guidance (77387). Do not bill standard EBRT codes on the same day as SBRT delivery codes. |
Hematology-Oncology Billing: Bone Marrow (38220-38222), Flow Cytometry (88184-88189), and Transfusion
| CPT Code | Description | Oncology Billing Note |
|---|---|---|
| 38220 / 38221 / 38222 | Bone Marrow Aspiration (38220), Core Biopsy (38221), Combined (38222) | Bill 38222 when both aspiration and biopsy are performed, not 38220 and 38221 separately. Billing both individually when 38222 applies is an unbundling error. |
| 88184-88189 | Flow Cytometry by Marker Count: First Marker (88184) Through Each Additional Beyond 8 (88189) | Units billed must match the number of markers documented in the pathology report. 88185 for markers 2-8, 88189 for each beyond 8. Confirm marker count before billing. |
| 36430 / 36440 | Blood Transfusion: Initial Unit (36430) and Each Additional Unit (36440) | 36440 for each subsequent unit transfused. Document each unit, blood product type, and clinical indication. Bill administration code in addition to the blood product supply code. |
Oncology Drug J-Code Billing: Chemotherapy, Immunotherapy, and Targeted Therapy HCPCS Codes
| Code Type | Description | Oncology Billing Note |
|---|---|---|
| J9000-J9999 | Chemotherapy Drug J-Codes: Billed per Unit Administered with NDC Number Required | Units must match the documented administered dose. Attach the NDC number of the specific drug lot dispensed. Missing NDC generates automatic denial on Medicare and most commercial claims. |
| Immunotherapy J-Codes | Checkpoint Inhibitors, Monoclonal Antibodies, and CAR-T Therapy HCPCS Billing | Confirm the current J-code for each agent quarterly. Prior authorization required by all commercial payers and Medicare Advantage. Document diagnosis, line of therapy, and performance status in every authorization request. |
| Targeted Therapy | IV Agents Bill Under Part B; Oral Oncology Agents Typically Under Medicare Part D | IV targeted agents bill under Part B with J-codes. Oral agents are generally Part D and cannot be billed on a Part B claim. Confirm route and correct billing pathway before submission. |
Supportive Care Billing: Hydration (96360-96361), Anti-Nausea and G-CSF Drugs, and Oncology E/M
| CPT Code | Description | Oncology Billing Note |
|---|---|---|
| 96360 / 96361 | IV Hydration: Initial 31 Min to 1 Hour (96360) and Each Additional Hour (96361) | 96360 requires a minimum 31 minutes. Hydration billed concurrently with chemotherapy is bundled; bill separately only when hydration is the primary or sole infusion service that day. |
| Supportive Drug J-Codes | Anti-Emetics, G-CSF (J1442, J2505), and Other Supportive Care Drug HCPCS Codes | Each supportive drug has a distinct J-code. Bill with the appropriate administration code. G-CSF requires prior authorization from most payers. Confirm coverage before administering. |
| 99215 / 99205 | Oncology E/M: High-Complexity Established (99215) and New Patient (99205) | Active cancer treatment visits managing toxicity and adjusting high-risk regimens consistently qualify for 99215. Append modifier 25 when E/M is billed the same day as an infusion or procedure. |
Oncology Revenue Architecture
Three Revenue Streams Every Oncology Billing Service Must Protect
Oncology billing revenue does not just need to be captured. It needs to be protected. Drug cost exposure, prior authorization failures, and session billing gaps each represent distinct threats to practice financial viability that generalist billing companies are not built to manage.
Medical Oncology Drug Cost Protection and Chemotherapy Billing
Medical oncology billing revenue protection requires simultaneous management of prior authorization for every drug, J-code accuracy with NDC number documentation, infusion administration code capture with add-on hour documentation, and drug cost reconciliation against reimbursement rates. A single workflow failure in any of these four areas can generate a drug cost write-off that exceeds an entire month of billing fee revenue. This is not a revenue capture problem. It is a drug cost exposure problem that requires oncology-specific billing infrastructure.
Radiation Oncology Session Revenue and Treatment Course Billing
Radiation oncology billing revenue is earned session by session across multi-week treatment courses. Every unbilled treatment session is permanently lost revenue that was delivered but never collected. Treatment planning and simulation codes billed correctly at the start of each course, per-session delivery codes tracked against the treatment record throughout the course, and image guidance and special modality codes applied accurately on every applicable session determine whether the radiation oncology program collects its full earned revenue across every patient treated.
Hematology-Oncology Procedure Revenue and Blood Disorder Billing
Hematology-oncology billing covers bone marrow procedures, flow cytometry, blood transfusion administration, and the management of complex blood disorders under highly complex E/M codes. Each procedure category requires correct code selection based on the specific procedures performed and the number of units or markers documented. The hematology-oncology E/M visit, often the highest-complexity visit in any specialty given the patient acuity, is the most consistently undercoded encounter type in the program when providers default to mid-level codes regardless of documented complexity.
Why Choose MBC for Oncology Billing Services
When You Outsource Oncology Billing, You Need Cancer Care Specialists, Not Generalists
Every oncology practice that chooses to outsource oncology billing services to MBC gets a team built for the financial precision that cancer care revenue requires.
Dedicated Oncology Billing Specialists
Your practice is managed by coders and billers who work exclusively with medical oncology billing, radiation oncology billing, and hematology-oncology billing. Prior authorization management, J-code accuracy, NDC documentation, infusion add-on capture, session billing tracking, and oncology E/M optimization applied to every encounter, every treatment, every payer.
Oncology Practice Revenue and Drug Cost Dashboards
Real-time visibility into prior authorization status per drug and per patient, J-code denial rate by drug category, infusion add-on capture rate, radiation session billing completeness, drug cost versus reimbursement variance, and AR aging by payer. Your administrator sees drug cost exposure before it becomes a write-off, not after the quarter closes.
RCM Principal with Oncology Billing Expertise
Your first engagement is with a senior RCM Principal who understands oncology drug cost exposure, prior authorization requirements across medical and radiation oncology, chemotherapy infusion coding rules, and hematology procedure billing. Not someone reading from a generic oncology billing script.
HIPAA-Compliant EMR and Oncology System Integration
Secure integration with your oncology EMR, infusion management system, and pharmacy dispensing records. No manual re-entry of drug administration data, no charge lag on radiation sessions, no missed infusion hours. Every treatment encounter captured, coded, and submitted with complete NDC documentation before the billing window closes.
Oncology Prior Authorization and Compliance Monitoring
Per-patient, per-drug prior authorization tracking with 30-day renewal alerts before each treatment cycle. Authorization confirmed against drug, dose, and diagnosis before infusion scheduling. J-code compliance monitoring with NDC documentation audit on every drug claim. Drug cost exposure tracked against authorization status so the practice never administers a high-cost drug without confirmed coverage in place.
Quarterly Oncology Revenue Integrity Reviews
Strategic reviews covering prior authorization denial trends by drug category, J-code accuracy by drug class, infusion add-on capture rates, radiation session billing completeness, hematology procedure code accuracy, and E/M level distribution against patient acuity. Specific action plans your administrator can implement to protect oncology billing revenue across every treatment category.
Outsource Oncology Billing to MBC
Ready to See What Your Oncology Billing Services Team Is Actually Leaving Behind?
Schedule a 15-minute briefing with one of our Oncology RCM Principals. No sales pitch. We will review your prior authorization denial rate by drug category, J-code accuracy, infusion add-on capture rate, and drug cost exposure, and give your administrator a realistic annual recovery projection specific to your treatment mix and payer contracts. Explore our full medical billing services for oncology practices.